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Abstract
This is a retrospective cohort study of 20 children and adolescents to evaluate the clinical utility of a pharmacogenetic deci-
sion support tool. Twenty children and adolescents underwent pharmacogenetic testing between June 2014 and May 2017. 
All children and adolescents were evaluated at Puerta de Hierro University Hospital-Majadahonda (Madrid, Spain). We 
report the proportion of patients achieving clinical improvement, amelioration of side effects, and changes in number of 
drugs. Data normality was assessed with the Shapiro–Wilk test, and changes of pre- and post-pharmacogenetic testing were 
analyzed with the Wilcoxon test for paired samples. A two-sided p value threshold of 0.05 was considered for significance. 
Pharmacogenetic testing helped to improve the clinical outcome as measured by the Clinical Global Impressions (CGI) Scale 
in virtually all children (95%; 19 out of 20 children). The CGI improvement (CGI-I) was 2 (0.79) (range 1–4), 2.1 (0.56) 
(range 1–3), and 1.9 (0.99) (range 1–4) in foster and non-foster care children, respectively. Pharmacogenetic testing also 
helped to reduce the number of children using polypharmacy (from 65 to 45%), the mean number of drugs per children (from 
3.3 to 2.4 drugs, p = 0.017), and self-reported relevant side effects (p = 0.006). Pharmacogenetic testing helped to improve 
the clinical outcome, and to reduce polypharmacy and the number of drugs used in children and adolescents with severe 
mental disorders. More evidence using robust (i.e., clinical trials) independent studies is required to properly determine the 
clinical utility and cost-effectiveness of pharmacogenetic testing tools in children and adolescents with mental disorders.
Keywords Pharmacogenetic decision support tool · Pharmacogenetic testing · Mental disorder · Children · Personalized 
psychiatry · Polypharmacy
Abbreviations
ADHD  Attention deficit hyperactivity disorder
CGI Scale  The Clinical Global Impressions
CGI-S  The Clinical Global Impressions-Severity
CGI-I  The Clinical Global 
Impressions-Improvement
ECT  Electro convulsive therapy
MDD  Major depressive disorder
PGx  Testing pharmacogenetic testing
Background
An increasingly large proportion of the worldwide popula-
tion lives with a mental disorder. The worldwide prevalence 
of mental disorders is 20% in adult populations (Kessler 
et al. 2009; Steel et al. 2014), and 13.4% (95% CI 11.3–15.9) 
in children and adolescents (Polanczyk et al. 2015). Medi-
cations are frequently used to treat mental disorders, but 
“choosing the right medication for each patient is challeng-
ing” (Health Quality Ontario 2017). Indeed, a great propor-
tion of patients discontinue medication because of lack of 
response or adverse effects (Health Quality Ontario 2017). 
For instance, the treatment for major depressive disorder 
(MDD) does not achieve remission in approximately 50% 
of patients following two drug trials (Rush 2007). On the 
other hand, medications such as antipsychotics can produce 
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extra-pyramidal symptoms, metabolic syndrome, and eleva-
tion of blood prolactin, among others (Leucht et al. 2013).
Given the high proportion of lack of response and the 
patient’s need of achieving quick symptom relief, polyphar-
macy has become a frequent practice (Mrazek 2010). Even 
if support for polypharmacy is scarce (Stahl 2002), polyp-
harmacy and off-label use of psychotropic drugs are frequent 
in youth with mental disorders and have become a matter 
of concern worldwide (Olashore and Rukewe 2017). This 
is probably a consequence of the reality that the process of 
decision-making about the best drug choice for each patient 
still remains an empirical “trial-and-error process” (Mrazek 
2010).
In this context, pharmacogenomic and pharmacogenetic 
(PGx) testing may help to guide decision-making regard-
ing the best personalized prescription for each patient 
(Arandjelovic et al. 2017; Bousman and Hopwood 2016) 
by increasing the rate of response, lowering the rate of side 
effects (Haga and LaPointe 2013), and reducing psychiatric 
healthcare costs (Plothner et al. 2016). Children and adoles-
cents with mental disorders should benefit from the pharma-
cogenomic promise to use “safer and more effective drugs” 
(Freund and Clayton 2003). But even if the translation of 
pharmacogenomics to individualized psychiatry for children 
and adolescents has accelerated (Wehry et al. 2018), PGx 
testing is not routine, and proper study of clinical utility is 
being undertaken slowly (Bousman et al. 2017a).
This is a retrospective cohort study of 20 children and 
adolescents who underwent PGx testing using a particular 
pharmacogenetic decision support tool. Preliminary reports 
using this tool in adult samples are encouraging (Espadaler 
et al. 2016; Perez et al. 2017), but there are no publications 
in youth populations. The aim of the present study was to 
describe the clinical utility of Neuropharmagen for children 
with severe mental disorders under real-world conditions. 
The clinical utility was described in terms of clinical out-
come, decrease of either polypharmacy or the number of 
drugs used, and reduction in side effects.
Materials and methods
Study design
This is a retrospective cohort study of children and ado-
lescents with severe mental disorders who received treat-
ment and underwent PGx testing with Neuropharmagen 
at Puerta de Hierro University Hospital-Majadahonda 
(HUPH-M, Madrid, Spain) between June 2014 and May 
2017. Neuropharmagen is a pharmacogenomic-based 
precision medicine platform developed by AB-Biotics SA 
(Barcelona, Spain) to assist clinicians in drug selection 
(Perez et al. 2017). After gaining the approval of the ethics 
committee, we prepared a chart including the following 
information, which was extracted from the clinical files 
of each patient: (1) Diagnostic and Statistical Manual of 
Mental Disorders-Fourth Edition (DSM-IV) diagnoses 
and clinical severity as measured by the Clinical Global 
Impression Scale-Severity Component (CGI-S) (Busner 
and Targum 2007), (2) the main reasons for PGx testing, 
which were classified into three categories (poor clinical 
response, adverse events reported spontaneously, and the 
need by either the clinician or the parents/guardians of 
the child to confirm that the drug regimen was the best 
available choice for the patient), (3) pre- and post-PGx 
testing drug regime, (4) PGx testing recommendation, (5) 
clinical outcome (as measured by the improvement com-
ponent of the CGI, CGI-I) (Busner and Targum 2007), 
and (6) improvement (if any) of the self-reported relevant 
side effects collected using a non-validated question-
naire including neurologic side effects (dystonia, tremor, 
akathisia, seizures, and tics), lost/gained weight, accom-
modation disturbances, dry mouth, excessive sedation, pal-
pitations/tachycardia, nausea/vomiting, headache, galact-
orrhoea/amenorrhoea, excessive/reduced duration of sleep, 
and “others” side effects.
Study sample
We included 20 patients (10 children and adolescents living 
in residential foster care; and 10 children and adolescents 
who were not) evaluated at HUPH-M from June 1, 2014 to 
May 25, 2017. All patients were 17 years of age or younger 
and were diagnosed according to the Diagnostic and Statisti-
cal Manual of Mental Disorders-Fourth Edition (DSM-IV).
Genotyping and reporting of test results
All patients provided a saliva sample for DNA extraction 
and genotyping. The way DNA is usually extracted from 
saliva samples, how the genotyping of single-nucleotide 
polymorphisms (SNPs) is performed, and the PGx testing 
interpretative report of this tool is reported elsewhere (Perez 
et al. 2017). Basically, the current version of this pharmaco-
genetic decision support tool report provides three types of 
information: (1) pharmacogenomic information for 50 drugs, 
including antipsychotics, antidepressants, mood stabilizers, 
and other CNS drugs, derived from the analysis of SNPs 
in 25 genes associated with drug efficacy, metabolism, or 
specific adverse effects (e.g., extra-pyramidal symptoms or 
metabolic syndrome); (2) data on pharmacological interac-
tions; and (3) information on lifestyle influences and specific 
clinical conditions. The information is accessible through a 
Web-based computer-aided system.
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Change of medication after PGx testing
The information provided by PGx testing was always 
considered when making a medical decision, including 
putative changes in the drug regime. Choosing the right 
medication for each child was made as usual, including all 
available information (clinical diagnosis and symptoms, 
potential side effects, efficacy of drugs, etc.) but incorpo-
rating the information provided by the pharmacogenetic 
decision support tool.
Ethics
All patients and their legal guardians had provided writ-
ten informed consent for PGx testing. The study was 
approved by the Agencia Española de Medicamentos y 
Productos Sanitarios (AEMPS). The study protocol was 
approved by the IRB of the Puerta de Hierro University 
Hospital-Majadahonda (Madrid, Spain) (reference num-
ber 17.17; October 9, 2017). The study complied with the 
Helsinki Declaration.
Statistics
Data normality was assessed with the Shapiro–Wilk test. 
Because of the lack of normality detected, changes in pre- 
and post-PGx testing were analyzed with the Wilcoxon 
non-parametric test for paired samples, and correlation 
was measured with the Spearman non-parametric test. A 
two-sided p value threshold of 0.05 was considered for 
significance.
Results
Descriptive results
Characteristics of the 20 patients are shown in Table 1 [see 
also Table 1-Supplementary Material (SM) (foster care chil-
dren) and Table 2-SM (non-foster care children) for further 
information].
Poor clinical response was the most frequent reason for 
PGx testing (19 out of the 20 cases). Furthermore, before 
PGx testing, 13 (65%) children [7 (70%) and 6 (60%) of 
the foster care and non-foster care children, respectively] 
were on polypharmacy, as defined by the use of three or 
more concomitant psychotropic medications (Fontanella 
et al. 2014). Finally, self-reported clinically significant side 
effects were the second most frequently reported reason for 
using PGx testing (n = 9, 45%). Five (50%) and four (40%) 
of the foster care and non-foster care children spontaneously 
reported at least one side effect, respectively. Side effects 
included weight increase (n = 3), neck dystonia (n = 2), 
akathisia (n = 2), neck dystonia and akathisia (n = 2), head-
aches (n = 1), and excessive sedation (n = 1).
Clinical outcomes
We found clinical improvement as measured by the CGI-I 
in virtually all children (95%; 19 out of 20 children) after 
the use of PGx testing. The average CGI-I was 2 (0.79) 
(range 1–4) in the study population: 2.1 (0.56) (range 
1–3) and 1.9 (0.99) (range 1–4) in foster and non-foster 
care children, respectively. The CGI-S post-PGx testing 
(subtracting CGI-I to the basal CGI-S) was 3.8 (1.03) 
(range 0–6) (p < 0.001) (foster care children: 4.10 (0.87) 
Table 1  Main characteristics of the sample
FET Fisher’s exact test
All children Foster care children Non-foster care children Significance
Age ( SD) 14.6 ± 1.5 14 ± 1.49 15.2 ± 1.39 t = − 1.857, df = 18, p = 0.080
Gender (female, %) 11 (55%) 8 (80%) 3 (30%) FET p = 0.070
Main axis I diagnose Autistic disorder (299.00) (25%)
Attention-deficit hyperactivity 
disorder, combined subtype 
(314.01) (25%)
Autistic disorder 
(299.00) (50%)
Major depressive disorder 
(MDD), single episode (severe 
without psychotic features, 
296.23) (40%)
χ2 = 13.200, df = 6, p = 0.040
N of concomitant 
drugs pre-PGx 
testing (mSD)
3.3 ± 1.86 4 ± 2.26 2.6 ± 1.07 t = 1.769, df = 18, p = 0.094
N of concomitant 
drugs post- PGx 
testing (mSD)
2.4 ± 0.93 2.7 ± 0.94 2 ± 0.81 t = 1.769, df = 18, p = 0.094
CGI-S (pre-) 5.6 ± 0.98 6.2 ± 0.63 5.1 ± 0.99 t = 2.952, df = 18, p = 0.009
CGI-S (post-) 3.8 ± 1.03 4.1 ± 0.87 3.6 ± 1.17 t = 1.080, df = 18, p = 0.295
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(range 3–5) (p = 0.005); and non-foster care children: 3.6 
(1.17) (range 0–6) (p = 0.009) (see Fig. 1).
Polypharmacy
After PGx testing, 9 (45%) children [6 (60%) and 3 (30%) 
of the foster care and non-foster care children, respec-
tively] were on polypharmacy. In other words, there was a 
reduction of polypharmacy in 20% of the children (10% of 
foster care children and 30% of non-foster care children). 
There was also a reduction in the mean number of drugs 
per children, as they were on 2.4 ± 0.9 drugs on aver-
age (47 drugs/20 children: 2.7 drugs per foster care child 
and 2 drugs per non-foster care child), the change being 
statistically significant (p = 0.017) when the data were 
treated as a group (see Fig. 2). Of note, said reduction 
was strongly correlated to the number of drugs at baseline 
(Spearman r = 0.81, p < 0.001), indicating that patients 
taking a higher number of drugs were those benefitting 
from a larger reduction.
Adverse events (side effects)
In all cases, the reported side effects were no longer a matter 
of concern after the change in the treatment regimen follow-
ing pharmacogenetic testing. Given that, at baseline, there 
were 0.6 ± 0.7 (range 0–2) relevant adverse effects per par-
ticipant; their complete disappearance post- pharmacoge-
netic testing was statistically significant (p = 0.006).
Discussion
The present naturalistic retrospective descriptive cohort 
study of 20 children suggests that pharmacogenetic testing 
may have clinical utility in improving clinical outcomes, 
reducing polypharmacy, reducing the number of drugs used 
per child, and reducing side effects in children with severe 
mental disorders. Two previous studies (one retrospective 
naturalistic multicenter study and a randomized double-blind 
clinical trial) in adults with mental disorders further sup-
port the clinical utility of this particular pharmacogenetic 
decision support tool (Espadaler et al. 2016; Perez et al. 
Fig. 1  Clinical outcome as 
measured by the CGI pre- and 
post-PGx testing
Fig. 2  Reduction in the number 
of drugs per child pre- and 
post- PGx testing). Foster and 
non-foster are shown separately 
to illustrate that the reduction 
is found in both groups. The 
global reduction in number 
of drugs was statistically sig-
nificant (p = 0.017). However, 
the number of subjects in each 
subgroup was too small for the 
reduction to reach statistical sig-
nificance within each subgroup 
(p = 0.105 and p = 0.071 in fos-
ter and non-foster, respectively)
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2017). This is in keeping with the recent literature suggest-
ing the clinical utility of other pharmacogenetic tools such 
as Amplichip (Chau and Thomas 2015). Furthermore, two 
recent reviews, one of them focused on child psychiatry, 
suggest that even if the improvement in health outcomes and 
the cost-effectiveness of pharmacogenomics are not consist-
ently replicated, PGx testing appears to be a promising tool 
that might help in predicting treatment response and adverse 
events (Rosenblat et al. 2017; Wehry et al. 2018).
The most relevant finding of the present study is that 
pharmacogenetic testing contributed to improved clinical 
outcomes as measured by the CGI-I in nearly all children. 
The median CGI-I score of 2 (much improved) (Busner 
and Targum 2007) reflects that, in some cases, the clinical 
improvement was dramatic, particularly in foster care chil-
dren. In a recent systematic review of clinical trials and cost-
effectiveness studies of PGx testing on the clinical outcome 
of MDD, the authors concluded that clear-cut demonstra-
tion of improved health outcomes and cost-effectiveness of 
pharmacogenomics were not yet supported with replicated 
evidence; however, they recognized that some studies have 
reported promising results for the clinical utility of PGx 
testing (Rosenblat et al. 2017). In another review of PGx 
testing in child and adolescent psychiatry, the authors con-
cluded that PGx testing might help in predicting treatment 
response and adverse events, as well as medication selection 
in children and adolescents with depressive disorders, anxi-
ety disorders, and ADHD (Wehry et al. 2018). Furthermore, 
in a case report using the Genecept assay testing (Geno-
mind, Chalfont, PA, USA), the authors reported that PGx 
testing helped in prescribing the most effective medication, 
thus illustrating “how pharmacogenetics and psychiatry can 
potentially interface to provide more informed decision-
making regarding use of psychotropic medications” (Smith 
et al. 2015).
We also found a notable reduction in polypharmacy and 
the number of drugs per child, the effect being statistically 
significant. Moreover, the reduction effect was larger in 
those patients taking more drugs. Clinicians usually turn to 
polypharmacy in a desperate intent to find the “right com-
bination” (Mrazek 2010) and control psychiatric symp-
toms. Furthermore, the pressure to promptly resolve psy-
chiatric symptoms makes pharmacological options more 
attractive, thus favoring polypharmacy (Diaz-Caneja et al. 
2014; Olashore and Rukewe 2017). However, polyphar-
macy increases the risk of drug–drug interactions, side 
effects, and non-compliance (Olashore and Rukewe 2017; 
Stahl 2002). Polypharmacy was particularly worrisome in 
our sample of foster care children. This was not surprising 
given that foster care children displayed more severe men-
tal disorders. Foster care children are more likely to use 
mental health services than non-foster care children (Hal-
fon et al. 1992), and the use of polypharmacy is frequent. 
In a study of 240 youths in foster care, 61% were taking 
two or more prescribed drugs (Brenner et al. 2014), which 
is comparable with the 80% that we reported here. Fur-
thermore, a few non-pharmacological options have been 
successful in reducing behavioral problems in foster care 
youth. For instance, Multidimensional Treatment Foster 
Care for Preschoolers was less efficient than regular foster 
care in diminishing the severity of externalizing problems 
in a recent study (Jonkman et al. 2017).
The reduction of polypharmacy was accompanied with 
the resolution of all clinically significant side effects. 
This is not surprising, as polypharmacy is related to over-
medication and side effects (Mrazek 2010; Olashore and 
Rukewe 2017). This is important, because children are 
particularly vulnerable to side effects, particularly extra-
pyramidal symptoms, when using antipsychotics (Garcia-
Amador et al. 2015). Our results are in keeping with a 
12-week double-blind randomized controlled trial in 316 
adult patients with MDD using the same pharmacogenetic 
test. The authors reported that the use of PGx testing was 
associated with an increased likelihood of achieving bet-
ter tolerability (frequency, intensity, and burden of side 
effects) (Perez et al. 2017). This finding is particularly 
relevant for our children with autism spectrum disorders, 
as they are “less equipped to express potential side effects 
of medications or have full remission of symptoms with 
medication” (Bose-Brill et al. 2017).
Strengths of the present study include: (1) the naturalis-
tic, real-world clinical practice design and (2) a population 
of particular interest: children and adolescents with severe 
mental disorders. To our knowledge, there are no previous 
reports of clinical use of any particular PGx test in chil-
dren and adolescents except for a two-case report study 
using Neuropharmagen (De Crescenzo et al. 2016) and 
a single case report using Genecept assay testing (Smith 
et al. 2015). Limitations include: (1) a small sample size; 
(2) the particularly severe profile, particularly of foster 
care children, which are not representative of the “regular” 
children followed-up at mental health centers; (3) the lack 
of clinical scales apart from CGS-S and CGS-I; (4) the 
lack of a proper control group; (5) the use of one of the 
potential definitions of polypharmacy (Chen et al. 2011; 
Fontanella et al. 2014) and clinical utility (Bousman and 
Hopwood 2016; de Leon 2016); and, finally, (6) our lack 
of opportunity to conduct a cost-effectiveness analysis. All 
these limitations put together imply that our data cannot 
be generalized to all children and adolescents with mental 
disorders. Additional studies with more detailed clinical 
scales, larger populations, and a randomized double-blind 
design (i.e., clinical trials) are required to confirm the 
clinical utility of PGx testing in the general population 
of children and adolescents with mental health disorders.
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Conclusion
Preliminary reports of different pharmacogenetic deci-
sion support tools are promising (Espadaler et al. 2016; 
Smith et al. 2015; Chau and Thomas 2015). Our study is 
in keeping with these studies but in a youth population, 
and suggests that PGx testing might help clinicians in the 
process of decision-making about the best drug choice for 
a particular child diagnosed with a mental disorder. How-
ever, more evidence concerning the clinical utility of PGx 
testing in youth is warranted. All pharmacogenetic deci-
sion support tools will probably have to face similar prob-
lems. For instance, Amplichip still must compile evidence 
regarding genotype accuracy, predictions of phenotypes 
from genotypes, and the translation of genotype-to-phe-
notype predictions into clinical utility (Chau and Thomas 
2015). Moreover, the body of evidence regarding the Gen-
eSight test is very low and mostly limited to depression 
(Health Quality Ontario 2017). Thus, more evidence is 
required to properly determine the clinical utility and cost-
effectiveness of PGx testing in children and adolescents, 
and whether some patient profiles are more likely to ben-
efit than others.
Some have considered “the moral treatment of mental 
patients, electro-convulsive therapy (ECT), and psycho-
tropic medications”, along with addressing the comorbidi-
ties of mental illnesses with chronic physical illnesses as 
the first, second, third, and fourth revolutions in psychiatry 
(Gautam 2010). Personalized psychiatry may constitute 
the fifth psychiatric revolution. To achieve this aim, per-
sonalized psychiatry must demonstrate its clinical utility 
by mounting more evidence and becoming part of the clin-
ical routine, and this would not be easy. A roadmap for 
“pharmacogenetic tests to be incorporated by prescribers 
into long-term practice” has recently been published (de 
Leon 2016; de Leon and Spina 2016). Furthermore, the 
universal adoption of the different PGx tools should rely 
on independent evaluations (Bousman et al. 2017b). In any 
case, as warned by Bousman et al. (2018), PGx testing will 
never provide “definitive prescribing advice for psychi-
atric drugs” or substitute for a good clinician. PGx tests 
just provide additional information for clinicians to assist 
them in choosing the right drug within the biopsychosocial 
context of a particular patient (Arandjelovic et al. 2017; 
Bousman et al. 2018) who is probably not diagnosed with 
a disease but rather a syndrome (de Leon 2016).
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